Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Postmenopausal atrophic vaginitis, along with vasomotor symptoms and sleep disorders, is one of the most troublesome symptoms of menopause. However, many women do not manage this symptom properly due to insufficient knowledge of the symptoms or sexual embarrassment. With appropriate treatment, many postmenopausal women can experience relief from discomforts, including burning sensation or dryness of the vagina and dyspareunia. Topical lubricants and moisturizers, systemic and local estrogens, testosterones, intravaginal dehydroepiandrosterones (DHEAs), selective estrogen receptor modulators, and energy-based therapies are possible treatment modalities. Systemic and local estrogen therapies effectively treat genitourinary syndrome of menopause (GSM), but they are contraindicated in patients with breast cancer, for whom lubricants and moisturizers must be considered as the primary treatment. Intravaginal DHEA and ospemifene can be recommended for moderate to severe GSM; however, there is insufficient data on the use of intravaginal DHEA or ospemifene in patients with breast cancer, and further studies are needed. Energy-based devices such as vaginal laser therapy reportedly alleviate GSM symptoms; however, the U.S. Food and Drug Administration warning has recently been issued because of complications such as chronic pain and burning sensations of the vagina. To summarize, clinicians should provide appropriate individualized treatment options depending on women’s past history, symptom severity, and chief complaints.
Abstract
Postmenopausal atrophic vaginitis, along with vasomotor symptoms and sleep disorders, is one of the most troublesome symptoms of menopause. However, many women do not manage this symptom properly due to insufficient knowledge of the symptoms or sexual embarrassment. With appropriate treatment, many postmenopausal women can experience relief from discomforts, including burning sensation or dryness of the vagina and dyspareunia. Topical lubricants and moisturizers, systemic and local estrogens, testosterones, intravaginal dehydroepiandrosterones (DHEAs), selective estrogen receptor modulators, and energy-based therapies are possible treatment modalities. Systemic and local estrogen therapies effectively treat genitourinary syndrome of menopause (GSM), but they are contraindicated in patients with breast cancer, for whom lubricants and moisturizers must be considered as the primary treatment. Intravaginal DHEA and ospemifene can be recommended for moderate to severe GSM; however, there is insufficient data on the use of intravaginal DHEA or ospemifene in patients with breast cancer, and further studies are needed. Energy-based devices such as vaginal laser therapy reportedly alleviate GSM symptoms; however, the U.S. Food and Drug Administration warning has recently been issued because of complications such as chronic pain and burning sensations of the vagina. To summarize, clinicians should provide appropriate individualized treatment options depending on women’s past history, symptom severity, and chief complaints.
참고문헌 (43)
- Portman DJ, "Genitourinary syndrome of menopause:new terminology for vulvovaginal atrophy from the International Society for the Study of Womenʼs Sexual Health and the North American Menopause Society", Maturitas, 79, pp.349~354 (2014)
- Robinson D, "The role of estrogens in female lower urinary tract dysfunction", Urology, 62(4 Suppl 1), pp.45~51 (2003)
- Mac Bride MB, "Vulvovaginal atrophy", Mayo Clin Proc, 85, pp.87~94 (2010)
- O'Connell TX, "Non-neoplastic epithelial disorders of the vulva", Am Fam Physician, 77, pp.321~326 (2008)
- Calleja-Agius J, "Urogenital atrophy", Climacteric, 12, pp.279~285 (2009)
- Kingsberg SA, "Vulvar and vaginal atrophy in postmenopausal women : findings from the REVIVE(REal Womenʼs VIews of Treatment Options for Menopausal Vaginal ChangEs)survey", J Sex Med, 10, pp.1790~1799 (2013)
- Nappi RE, "Vulvar and vaginal atrophy in four European countries : evidence from the European REVIVE Survey", Climacteric, 19, pp.188~197 (2016)
- Al-Baghdadi O, "Topical estrogen therapy in the management of postmenopausal vaginal atrophy : an up-to-date overview", Climacteric, 12, pp.91~105 (2009)
- Chen J, "Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness : a multicenter, randomized, controlled, open-label, parallel-group, clinical trial", J Sex Med, 10, pp.1575~1584 (2013)
- Herbenick D, "Association of lubricant use with womenʼs sexual pleasure, sexual satisfaction, and genital symptoms : a prospective daily diary study", J Sex Med, 8, pp.202~212 (2011)
- Use and procurement of additional lubricants for male and female condoms: WHO, "UNFPA", FHI360:advisory note, World Health Organization, pp.2012, ~[DOI]
- Sandhu RS, "In vitro effects of coital lubricants and synthetic and natural oils on sperm motility", Fertil Steril, 101, pp.941~944 (2014)
- Voeller B, "Mineral oil lubricants cause rapid deterioration of latex condoms", Contraception, 39, pp.95~102 (1989)
- Edwards D, "Treating vulvovaginal atrophy", genitourinary syndrome of menopause : how important is vaginal lubricant and moisturizer composition, 2016, pp.19, 151~161
- Goetsch MF, "A practical solution for dyspareunia in breast cancer survivors : a randomized controlled trial", J Clin Oncol, 33, pp.3394~3400 (2015)
- The North American Menopause Society(NAMS), "The 2020genitourinary syndrome of menopause position statement of The North American Menopause Society", Menopause, 27, pp.976~992 (2020)
- Simon JA, "Clarifying Vaginal Atrophyʼs Impact on Sex and Relationships(CLOSER)survey : emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners", Menopause, 21, pp.137~142 (2014)
- Shifren JL, "Genitourinary syndrome of menopause", Clin Obstet Gynecol, 61, pp.508~516 (2018)
- Eugster-Hausmann M, "Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets", Climacteric, 13, pp.219~227 (2010)
- Santen RJ, "Treatment of urogenital atrophy with low-dose estradiol : preliminary results", Menopause, 9, pp.179~187 (2002)
- Coelingh Bennink HJ, "Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women", Maturitas, 91, pp.93~100 (2016)
- North American Menopause Society, "The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women : 2007 position statement of The North American Menopause Society", Menopause, 14(3 Pt 1), pp.355~369 (2007)
- Labrie F, "Efficacy of intravaginal dehydroepiandrosterone(DHEA)on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause", Menopause, 25, pp.1339~1353 (2018)
- Ke Y, "Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA", Horm Mol Biol Clin Investig, 24, pp.117~129 (2015)
- Sauer U, "Efficacy of intravaginal dehydroepiandrosterone(DHEA)for symptomatic women in the perior postmenopausal phase", Maturitas, 116, pp.79~82 (2018)
- Traish AM, "Role of androgens in female genitourinary tissue structure and function : implications in the genitourinary syndrome of menopause", Sex Med Rev, 6, pp.558~571 (2018)
- Salinger SL, "Proliferative effect of testosterone propionate on human vaginal epithelium", Acta Endocrinol (Copenh), 4, pp.265~284 (1950)
- Panay N, "Testosterone treatment of HSDD in naturally menopausal women : the ADORE study", Climacteric, 13, pp.121~131 (2010)
- Simon J, "Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder", J Clin Endocrinol Metab, 90, pp.5226~5233 (2005)
- Bell RJ, "A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy", Menopause, 25, pp.704~709 (2018)
- Raghunandan C, "A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women", J Sex Med, 7, pp.1284~1290 (2010)
- Davis SR, "Global consensus position statement on the use of testosterone therapy for women", Climacteric, 22, pp.429~434 (2019)
- Portman DJ, "Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy", Menopause, 20, pp.623~630 (2013)
- Kagan R, "A randomized, placebo-and active-controlled trial of bazedoxifene", conjugated estrogens for treatment of moderate to severe vulvar, Menopause, pp.2010, 17[DOI]
- Becorpi A, "Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors : clinical, immunological, and microbiological aspects", Lasers Med Sci, 33, pp.1047~1054 (2018)
- Macrene R. Alexiades, "Fractional CO2 laser treatment of the vulva and vagina and the effect of postmenopausal duration on efficacy", Lasers in Surgery and Medicine, 53(2), pp.185~198 (2021), Wiley[DOI]
- Arroyo C, "Fractional CO2 laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women", Int J Womens Health, 9, pp.591~595 (2017)
- Elia D, "Genitourinary syndrome of menopause(GSM)and laser VEL : a review", Horm Mol Biol Clin Investig, 41 (2019)
- Gambacciani M, "Vaginal erbium laser : the second-generation thermotherapy for the genitourinary syndrome of menopause", Climacteric, 18, pp.757~763 (2015)
- Gambacciani M, "Rationale and design for the Vaginal Erbium Laser Academy Study(VELAS) : an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence", Climacteric, 18(Suppl 1), pp.43~48 (2015)
- Kamilos MF, "New therapeutic option in genitourinary syndrome of menopause : pilot study using microablative fractional radiofrequency", Einstein (Sao Paulo), 15, pp.445~451 (2017)
- Faubion SS, "Genitourinary syndrome of menopause : management strategies for the clinician", Mayo Clin Proc, 92, pp.1842~1849 (2017)
- Faubion SS, "Recognition and management of nonrelaxing pelvic floor dysfunction", Mayo Clin Proc, 87, pp.187~193 (2012)